Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Two Pharmaceutical Companies to Develop a Recombinant Factor VIIa Product
 

GTC Biotherapeutics, Inc., of Framingham, MA, and Paris-based LFB-Biotechnologies will collaborate on the development of therapeutic products using recombinant plasma proteins and monoclonal antibodies (identical antibodies used in the production of pharmaceuticals). Their first collaborative product is a recombinant human factor VIIa (rhFVIIa) therapy. The rhFVIIa will be developed from the milk of GTC’s transgenic rabbits. Transgenic animals, such as cows and rabbits, are produced using externally introduced genes that are designed to trigger the production of specific human proteins in their milk. These proteins are then purified for other therapeutic uses, such as the treatment of patients with bleeding disorders.

The agreement states that GTC will develop a production system for the products and will hold exclusive commercial rights in North America. LFB will be responsible for clinical development and regulatory review of the first program of the collaboration and will have exclusive commercial rights in Europe. GTC Biotherapeutics, Inc., develops, produces and commercializes proteins through transgenic animal technology. LFB is a leading European producer of plasma-derived medical products, including those for hemostasis.

Source: America’s Blood Centers Newsletter, October 6, 2006

 

This section of our Web site is sponsored by: